ABCB10 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the LoVo colorectal adenocarcinoma line, designed for loss-of-function studies of the ABCB10 gene. The polyclonal knockout model comprises a mixture of edited alleles, providing a robust and bias-free system to investigate ABCB10-dependent functions.
The parental LoVo cell line is a widely used colorectal adenocarcinoma model originating from a lymph node metastasis. LoVo cells harbor mutations in KRAS and TP53 and display a microsatellite instability-high (MSI-H) phenotype, representing a clinically relevant subtype. These epithelial cells are employed in studies of metastasis, metabolic reprogramming, and therapeutic resistance, offering a pertinent background for exploring ABCB10 biology in cancer.
ABCB10 is a mitochondrial inner membrane transporter that exports heme precursors like ALA, driving heme biosynthesis. Its expression is controlled by transcription factors GATA1, NRF2, and HIF-1??, linking it to erythroid differentiation, antioxidant defense, and hypoxia. ABCB10 activity impacts ALAS2 and ferrochelatase (FECH), the terminal enzyme in heme synthesis. Physically, ABCB10 interacts with FECH, mitoferrin, and ABCB7, coordinating iron delivery and heme production. Gene disruption therefore uncouples heme synthesis, impairs mitochondrial respiration, and elevates oxidative stress.
In LoVo cells, ABCB10 knockout is especially impactful because these cancer cells depend on mitochondrial function and iron metabolism for growth and redox balance. Heme is critical for respiratory chain assembly and antioxidant enzymes. Loss of ABCB10 leads to reduced heme levels, respiratory chain deficiency, ROS accumulation, and increased susceptibility to oxidative damage, mirroring aspects of congenital sideroblastic anemia and erythropoietic protoporphyria. This makes the model valuable for dissecting heme metabolism’s role in colorectal cancer metabolic reprogramming.
Applications include studying heme-dependent processes such as mitochondrial respiration, iron handling, and oxidative stress signaling. Assays can involve RT-qPCR and Western blotting for ALAS2 and FECH, heme quantification, Seahorse metabolic flux analysis, flow cytometry for mitochondrial membrane potential, ROS measurements, and viability tests with H2O2. The polyclonal population also enables examination of GATA1, NRF2, and HIF-1?? regulation in a cancer context. For further information, contact Ascent Research.
